ICER puts fair mavacamten price at between $12,000 to $15,000 despite $75,000 forecasts
At a meeting this month, an Institute for Clinical and Economic Review (ICER) committee will assess the comparative clinical effectiveness and value of Bristol Myers Squibb’s (NYSE: BMY) mavacamten for the treatment of hypertrophic cardiomyopathy (HCM).
They will consider an ICER report on mavacamten, a drug acquired by BMS in its $13.1 billion buy of Brisbane, USA-based heart specialist MyoKardia.
"Clinical experts differ in their opinions about the long-term clinical implications of mavacamten reducing left ventricular ejection fraction"The ICER report has been updated based on comments received from patient groups, clinicians, drug manufacturers, and other stakeholders.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze